[Remote] Executive Director, CMC Quality Assurance at Abata Therapeutics

Remote

Apply Now

Not SpecifiedCompensation

N/AExperience Level

N/AJob Type

Not SpecifiedVisa

N/AIndustries

Requirements

Experience with combination product drug delivery systems
Expertise in leading QA efforts
Experience collaborating and influencing CDMO’s, laboratory, and pack/label vendors
Knowledge of FDA, EMA, and other global regulatory requirements for combination products
Experience with GMP and GLP compliance
Experience with supplier and contract manufacturer audits, qualification, and ongoing performance monitoring
Experience with regulatory submissions (IND, BLA, IDE, PMA)
Experience with Event (deviation, complaint, issue) and Corrective/Preventive Action (CAPA) process

Responsibilities

Develop and execute the company’s QA strategy across drug and device development and manufacturing
Lead and scale the QA team, including specialists in pharmaceutical and medical device quality
Oversee the Event (deviation, complaint, issue) and Corrective/Preventive Action (CAPA) process
Support the Quality Compliance Sr. Director with supplier and contract manufacturer audits, qualification, and ongoing performance monitoring
Guide technical development quality oversight—provide quality input to process development, technology transfer, comparability and stability strategies; approve key technical protocols and reports
Represent QA on governance forums (Change Review Board, Inventory & I&OP, CMC Team Review, Design Review Committee) and during health authority inspections as the primary product quality contact
Support regulatory submissions (IND, BLA, IDE, PMA) and serve as QA lead on submission reviews
Collaborate cross-functionally with Clinical, Regulatory, CMC, and Engineering teams to embed quality in a phase-appropriate manner
Provide QA support to nonclinical studies as needed (e.g. perform GLP audit of toxicology study protocols and reports)

Skills

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free